Cryptosporidiosis Drug Discovery: Opportunities and Challenges
详细信息 查看全文
- 作者：Ujjini H. Manjunatha ; Alexander T. Chao ; F. Joel Leong ; Thierry T. Diagana
- 刊名：ACS Infectious Diseases
- 出版年：2016
- 出版时间：August 12, 2016
- 年：2016
- 卷：2
- 期：8
- 页码：530-537
- 全文大小：370K
- ISSN：2373-8227
文摘
The apicomplexan parasite Cryptosporidium is the second most important diarrheal pathogen causing life-threatening diarrhea in children, which is also associated with long-term growth faltering and cognitive deficiency. Cryptosporidiosis is a parasitic disease of public health concern caused by Cryptosporidium parvum and Cryptosporidium hominis. Currently, nitazoxanide is the only approved treatment for cryptosporidium infections. Unfortunately, it has limited efficacy in the most vulnerable patients, thus there is an urgent need for a safe and efficacious cryptosporidiosis drug. In this work, we present our current perspectives on the target product profile for novel cryptosporidiosis therapies and the perceived challenges and possible mitigation plans at different stages in the cryptosporidiosis drug discovery process.